Open Access

MicroRNA‑21‑5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma

  • Authors:
    • Changfu Liu
    • Zhou Tong
    • Jingyu Tan
    • Zengxi Xin
    • Zhiying Wang
    • Luming Tian
  • View Affiliations

  • Published online on: September 2, 2019     https://doi.org/10.3892/etm.2019.7970
  • Pages: 3543-3551
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to analyze the role of microRNA (miRNA)‑21‑5p in tongue squamous cell carcinoma (TSCC), predict the target gene of miR‑21‑5p and provide novel strategies for gene therapy in TSCC treatment. The expression levels of miRNA‑21‑5p in TSCC tissues were analyzed using reverse transcription quantitative polymerase chain reaction, and the effects of miRNA‑21‑5p on cell proliferation, invasion and apoptosis and the expression levels of target protein PDCD4 in the Cal 27 and SCC9 cell lines were determined. PI3K/AKT/Forkhead Box O1 (FOXO1) pathway‑associated protein expression levels were evaluated by western blot analysis. miRNA‑21‑5p was consistently upregulated in TSCC tissues compared with normal tissues. Inhibition of miR‑21‑5p inhibited cell proliferation and invasion, and promoted cell apoptosis. A luciferase reporter assay confirmed that PDCD4 was the target of miR‑21‑5p. Inhibition of miRNA21‑5p suppressed the PI3K/Akt/FOXO1 signaling pathway. The results from the present study indicated that miR‑21‑5p‑targeting PDCD4 suppresses apoptosis in human TSCC cell lines. This anti‑apoptotic effect was achieved by regulating the PI3K/Akt/FOXO1 signaling pathway. These data represent the basis for a promising novel strategy for the treatment of TSCC.

Introduction

Tongue squamous cell carcinoma (TSCC) is the most common type of oral malignancy, accounting for 40–50% of all cases (1). TSCC exhibits the characteristics of high malignancy, rapid growth and marked levels of infiltration; furthermore, the tongue has abundant lymphatic vessels and blood circulation within its structure, which often results in TSCC progression to lymph node metastasis at earlier stages, and it seriously affects the voice, chewing and swallowing ability of the patients (24). At present, treatment of TSCC primarily relies on surgery, and treatment via radiotherapy and chemotherapy is auxiliary. However, the 5-year survival rate of patients is only 32–54% following comprehensive treatment (5,6). Therefore, identifying effective treatment methods is essential to improve survival rates for these patients.

Current research regarding TSCC focuses on microRNAs (miRNAs), and the function of miRNAs has preliminarily been identified. miRNA are small non-coding RNA molecules measuring 18–23 nucleotides in length. Although miRNAs have a small molecular weight, they serve a role in the transcriptional level of human cells and regulates numerous important biological functions of both plant and animal organisms, and in human tumors (7,8).

mi-21-5p is one of the most important members of the miRNA family, and it is closely associated with the occurrence and development of cancer. miRNA-21-5p, located on chromosome 17q23.1, has been identified in numerous different types of tumors, which indicates that it may exhibit enhanced expression levels that correspond with disease development. Jiang et al (9) revealed that miRNA-21-5p was upregulated in gastric cancer tissues and SGC-7901 cells, and that the knockdown of miRNA-21-5p suppressed cell proliferation, migration and invasion, and the inflammatory response. The identification of miRNAs and their expression profiles among different diseases indicates that miRNA-21 may serve as a potential biomarker (9). However, the role of miR-21-5p in TSCC and its associated underlying molecular mechanisms have not yet been reported.

In the present study, the expression levels of miR-21-5p in TSCC were investigated, and the apoptotic effect of miRNA-21-5p on human TSCC Cal 27 and SCC9 cell lines was examined. The results revealed that the PI3K/AKT signaling pathway serves a role in the underlying molecular mechanism of the disease.

Materials and methods

Patients and tissue samples

In total, 40 tumor tissue samples were obtained from patients with TSCC who had been admitted to the Department of Oral and Maxillofacial Surgery, Second Affiliated Hospital of Jinzhou Medical University (Jinzhou, China) between January 2017 and June 2018, including 24 males and 16 females, aged 38–76 years, with a median age of 54 years. None of the patients received chemotherapy or radiotherapy. In addition, 40 cases of normal tissues (adjacent non-cancerous tissues) were obtained from the Second Affiliated Hospital of Jinzhou Medical University. The inclusion criteria were as follows: All patients were diagnosed with TSCC via pathology, and no radiation therapy or chemotherapy was performed prior to biopsy. The exclusion criteria were as follows: Patients with one or more of the following conditions were excluded: i) Infectious disease; ii) acute cardiovascular and cerebrovascular diseases; iii) rheumatic disease; iv) diabetes; or v) other tumors.

The present study was approved by the Ethical Committee of Jinzhou Medical University on October 26, 2016 (approval no. JZH2016052). Written informed consent was obtained from all patients included in the present study.

Hematoxylin and eosin (H&E) staining

TSCC tissues were fixed (>24 h at room temperature) in 4% paraformaldehyde and embedded in paraffin. Paraffin-embedded samples were then sliced into 4 µm sections and resected specimens were dewaxed in xylene, washed in distilled water and stained with hematoxylin and eosin at room temperature for 5 min. Pathological alterations of myocardial tissue were observed under a light microscope (magnification, ×200).

Cell culture

TSCC Cal 27 and SCC9 cell lines were purchased from The Cell Bank of Type Culture Collection of Chinese Academy of Sciences. The Cal 27 cell line was cultured with Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO2 incubator at 37°C and saturated humidity. The SCC9 cell line was incubated with RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS in a 5% CO2 incubator at 37°C.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from the tissues or cell lines using TRIzol® reagent according to manufacturer's protocol. The cDNA was transcribed using a Prime Script™ RT Master Mixture according to the manufacturer's protocol (Takara Biotechnology Co., Ltd.). miR-21-5p in TSCC was detected using SYBR Prime Script miRNA RT-PCR kit (Takara Biotechnology Co., Ltd.). The thermocycling conditions were as follows: Pre-denaturation at 95°C for 1 min, followed by denaturation at 95°C for 15 sec, annealing at 60°C for 40 sec and extension at 72°C for 15 sec, for a total of 40 cycles. The primer sequences in the present study were as follows: hsa-miR-21-5p forward, 5′-GGGGTAGCTTATCAGACTGATG-3′; hsa-miR-21-5p reverse, 5′-TGTCGTGGAGCGGCAATTG-3′; U6: Forward, 5′-CGCTTCGGCACATATACTA-3′; U6 reverse, 5′-CGCTTCACGAATTTGCGTGTCA-3′; PDCD4 forward, 5′-TGTGCCAACCAGTCCA-3′; PDCD4 reverse, 5′-GATCCTAACTATGATGA-3′; GAPDH forward, 5′-TGTTGCCATCAATGACCCCTT-3′; GAPDH reverse, 5′-CTCCACGACGTACTCAGCG-3′. The expression levels of miRNA-21-5p were calculated using the 2−ΔΔCq method (10).

Transfection

miR-21-5p inhibitors were synthesized along with a corresponding negative control by Shanghai GenePharma Co., Ltd. Plasmid production and purification were performed by Shanghai GenePharma Co., Ltd. miR-21-5p inhibitor sequences (forward, 5′-UAGCUUAUCAGACUGAUGUUGA-3′ and reverse, 5′-TCAACATCAGTCTGATAAGCTA-3′) were cloned into the lentivirus without green fluorescence (Shanghai GeneChem Co., Ltd.). Polybrene (6 µg/ml; Shanghai GeneChem Co., Ltd.) and an appropriate dose of lentivirus (1×108) were added and incubated at 37°C for 24 h. Cells transfected with lentivirus were screened with puromycin to increase transfection efficiency. The transfection efficiency was additionally identified via PCR.

Cell Counting Kit-8 (CCK-8)

Next, 2,000 cells per well were seeded in the 96-well plate. Cell proliferation was detected using a CCK-8 assay (MedChemExpress) according to the manufacturer's protocol. The reproductive ability of cells was measured at 450 mm using a microplate reader.

Transwell assay

SCC-9 and Cal 27 cells were re-suspended without serum at a concentration of 1×105 cells/ml, and were then (200 µl) seeded into the upper well of Matrigel-coated (Sigma Aldrich; Merck KGaA) 8 µm pore Transwell inserts (Sigma Aldrich; Merck KGaA). DMEM (or RPMI-1640; Gibco; Thermo Fisher Scientific, Inc.) was added to the lower chamber containing 10% FBS. After 24 h of incubation at 37°C, cells in the chamber were removed with a cotton swab. Following fixed staining with 0.1% trypan blue for 20 min (Sigma Aldrich; Merck KGaA) at room temperature, images were captured at randomly selected fields and cells were counted under a light microscope (magnification, ×200).

Western blot analysis

Total protein was extracted from the cells using radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific, Inc.). A BCA protein assay kit was used to quantify the total protein. The proteins (30 µg) were separated via 10% SDS-PAGE. The gels were transferred to polyvinylidene difluoride (PVDF) membranes, which were blocked with 5% skimmed milk at room temperature for 2 h and incubated with anti-Bax (1:1,000; cat. no. ab32503), anti-Bcl2 (1:1,000; cat. no. ab182858), anti-PI3K (1:1,000, ab127617), anti-AKT (1:1,000; cat. no. ab179463), anti-phosphorylated Forkhead Box O1 (p-FOXO1; 1:800; cat. no. ab52857) and anti-GAPDH (1:2,000; cat. no. ab181602) antibodies (all from Abcam) overnight at 4°C. Following washing with PBS 3 times, the membranes were incubated with a secondary polyclonal peroxidase-labeled antibody (Goat Anti-Rabbit IgG; 1:4,000; Abcam; cat. no. ab205718) for 2 h, and detected using enhanced chemiluminescence (Thermo Fisher Scientific, Inc.). Quantification of the bands was performed using ImageJ software (Version d1.47; National Institutes of Health).

Propidium iodide (PI) and Annexin V staining

SCC9 and Cal 27 cells were collected, washed and resuspended. Following the addition of 5 µl Annexin V (BD Pharmingen; BD Biosciences) and 5 µl PI (BD Pharmingen; BD Biosciences), cells were incubated at room temperature for 20 min in the dark, washed with PBS and re-suspended with 300 ml of PBS. Cell apoptosis rate was calculated using Flow Jo software (v10.1.1 FlowJo LLC).

Target gene PDCD4 of miR-21-5p predicted by TargetScan

Targets of miR-21-5p were searched on TargetScan (www.targetscan.org/vert_71/) (11), and the results were further confirmed by PicTar29 (pictar.mdc-berlin.de/) and microRNA.org 30 (www.microrna.org) (12), suggesting PDCD4 is a potential target of miR-21-5p.

Luciferase reporter assay

The PDCD4 gene 3′-untranslated region (3′-UTR) sequence was cloned into a pMIR-REPORT vector (Ambion; Thermo Fisher Scientific, Inc.). Luciferase reporter plasmids of wild-type (WT)-PDCD4 mRNA and mutant (Mu)-PDCD4 mRNA were constructed using the clones. The cells were cultured for 24 h, while the PDCD4-UTR-pMIR plasmid and miR-21-5p inhibitors or Mu-PDCD4-UTR-pMIR plasmid and miR-21-5p inhibitors were co-transfected into cells using Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The relative luciferase activity of PDCD4 was detected using a Dual-Luciferase Reporter assay after transfection for 48 h. The Renilla luciferase values were normalized to that of firefly luciferase.

Statistical analysis

All data were presented as the mean ± standard deviation. Statistical analysis was performed using GraphPad Prism (v6.0; GraphPad Software Inc.). The data were assessed using the unpaired two-tailed Student's t-test for comparisons between two groups, or one-way analysis of variance followed by Kruskal-Wallis test and Dunn's multiple comparison post-hoc test for comparisons between >2 groups. Correlations between the miR-21-5p and PDCD4 gene were evaluated using Spearman's coefficient of correlation. P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical characteristics of patients with TSCC

The clinical characteristics of the patients with TSCC are presented in Table I. According to the Tumor-Node-Metastasis classification for TSCC (Union for International Cancer Control, UICC 2010, 7th edition) (13), the patients were divided into 4 stages: Stage I (n=4), stage II (n=12), stage III (n=17) and stage IV (n=7). Hematoxylin and eosin staining demonstrated that all patients had squamous cell carcinoma (Fig. 1A-D).

Table I.

Characteristic features of study subjects.

Table I.

Characteristic features of study subjects.

CharacteristicsPatients with TSCCNon-cancerous tissues
Age, years
  Range38–7635–71
  Mean ± SD57±9.2559±11.38
Smoking2120
Non-smoking1920
Drinking1520
Non-drinking2520
Local stimulation  5
  Residual roots and crowns of teeth  3
  Bad prosthesis  2
Tumor location
  Lingual margin26
  Lingual root  8
  Ventral of tongue  6
Tumor size
  T1  4
  T221
  T310
  T4  5
Lymph node involvement
  N023
  N+17
Pathological classification
  Squamous cell carcinoma40
Histological classification
  Well differentiated11
  Moderately differentiated24
  Poorly differentiated  5
Clinical stage
  I  4
  II12
  III17
  IV  7

[i] SD, standard deviation; TSCC, tongue squamous cell carcinoma.

miR-21-5p is upregulated in TSCC tissues

miR-21-5p was detected in TSCC tissues via RT-qPCR. As presented in Fig. 1B, the expression levels of miR-21-5p were significantly upregulated in TSCC tissue when compared with that of the control group (Fig. 1E).

Inhibition of miR-21-5p suppresses proliferation of Cal 27 cells and SCC9 cells

To determine the function of miR-21-5p, miR-21-5p was knocked down in the Cal 27 and SCC9 cell lines. Following miR-21-5p knockdown, the expression levels of miR-21-5p in Cal 27 and SCC9 cells were significantly decreased when assessed via RT-qPCR (Fig. 2A and B). The CCK-8 assay subsequently determined the proliferation ability of Cal 27 and SCC9 cells following miR-21-5p knockdown. The results revealed that miR-21-5p knockdown markedly inhibited the proliferation levels of Cal 27 and SCC9 cells (Fig. 2C).

Inhibition of miR-21-5p suppresses the invasion ability of Cal 27 and SCC9 cells

A Transwell assay was used to detect the invasive capabilities of Cal 27 and SCC9 cells. The results revealed that following miR-21-5p knockdown, the invasive capabilities of the Cal 27 and SCC9 cells decreased. The invasion assay demonstrated that the downregulation of miR-21-5p significantly inhibited the invasion capacity of Cal 27 and SCC9 cells (Fig. 3).

Inhibition of miR-21-5p promotes apoptosis of Cal 27 and SCC9 cells

To investigate the effect of miR-21-5p on Cal 27 and SCC9 cells, western blot analysis was used to detect apoptosis. The results revealed that the expression levels of the pro-apoptotic protein Bax increased significantly following miR-21-5p knockdown, while the expression level of anti-apoptosis protein Bcl2 was significantly decreased following knockdown of miR-21-5p. PI and Annexin V staining revealed that the early apoptosis of SCC9 and Cal 27 cells significantly increased following miR-21-5p knockdown (P<0.05). These results demonstrate that the downregulation of miR-21-5p expression promotes the apoptosis of Cal 27 and SCC9 cells (Fig. 4).

PDCD4 is the target of miR-21-5p

miRNAs affect the expression levels of mRNA by binding to their 3′-UTR, and the role of miR-21-5p is closely associated with the function of the target gene [for example phosphatase and tensin homolog (PTEN) and Smad7]. Target gene prediction indicated that PDCD4 may be a potential target of miR-21-5p (Fig. 5A). RT-qPCR was used to detect the expression levels of PDCD4 in TSCC tissues. The results revealed that the expression levels of PDCD4 decreased significantly in TSCC tissues (Fig. 5B), and the expression levels of miR-21-5p were negatively correlated with PDCD4 (Fig. 5C). To determine whether miRNA-21-5p directly targeted PDCD4, the present study cloned the 3′-UTR of PDCD4 downstream from the pMIR-CMV luciferase reporter. The results revealed that miRNA-21 decreased luciferase activity in WT-PDCD4-transfected cells (Fig. 5D). The luciferase assay demonstrated that PDCD4 was the target of miR-21-5p.

Apoptosis effect of miRNA-21-5p is determined via regulating the PI3K/Akt/FOXO1 signaling pathway

PI3K, AKT and p-FOXO1 protein expression levels were measured using western blot analysis (Fig. 6). The results revealed that the PI3K, AKT and p-FOXO1 protein expression levels were significantly decreased following miR-21-5p knockdown both in Cal27 and SCC9 cells (Fig. 6). Inhibition of miR-21-5p promoted apoptosis of Cal27 and SCC9 cells via regulating the PI3K/AKT/FOXO1 signaling pathway.

Discussion

miRNAs are factors that regulates biological responses including apoptosis, proliferation, differentiation and invasion. miRNAs account for ~1% of the genome, but they regulates ~60% of gene activity (14). Under the catalysis of RNA polymerase II, miRNA is transformed into primitive miRNAs with a cap structure and polyA tail, then the primitive RNA forms a stem-loop structure, which is transferred from the nucleus to the cytoplasm with the help of transporter exportin-5. This stem-loop structure is cut to form mature miRNAs. Finally, this stem-loop structure is cleaved to form mature miRNAs (15). The mature miRNAs bind to the RNA-induced silencing complex (RISC) to form an asymmetric RISC complex, which binds to the 3′-UTR on the mRNA of the target gene to regulate the expression of that target gene (15).

miR-21-5p is a member of the miRNA family, which is highly expressed in the serum of patients with a number of different types of tumors and serves an anti-apoptotic role (9). miR-21-5p is closely associated with the molecular mechanisms underlying drug resistance, cell invasion and metastasis of tumors, among other processes (1618). The results of the present study revealed that the expression levels of miRNA21-5p were upregulated in human TSCC, which was involved in the occurrence and development of tumors. CCK-8 and Transwell assay results demonstrated that the proliferative and invasive capabilities of the Cal 27 and SCC9 cell lines decreased following downregulation of miR-21-5p expression. Western blot analysis was used to detect the apoptotic and anti-apoptotic factors in the present study. The results revealed that downregulation of miR-21-5p promoted the apoptosis of Cal 27 and SC9 cells.

miR-21-5p directly or indirectly promotes the pathophysiological process of cells by regulating the expression of PDCD4, PTEN and tissue inhibitor of metalloproteinase-3 (19,20). Usually one miRNA targets multiple genes. As PDCD4 has been frequently reported as a target of miR-21-5p, the role of miR-21-5p in PDCD4 expression in TSCC requires additional study (21). In the present study, the luciferase reporter assay revealed that PDCD4-UTR-pMIR (WT) was significantly increased by miR-21-5p inhibitors. This indicated that PDCD4 was the target of microRNA-21-5p, but its mechanism requires additional experimental confirmation.

PI3K/AKT/FOXO1 is an important signaling pathway, which regulates progression in numerous different types of tumors. The PI3K/AKT pathway is closely associated with apoptosis. This pathway controls cell proliferation, growth, translation, migration and survival, and overactivation of this signaling pathway is associated with poor prognosis (21,22). Activated PI3K may activate downstream protein kinase AKT; Activated AKT is able to phosphorylate Bax, inactivate Bax and inhibit Bax and Bcl-2 to form dimers, thereby resulting in Bcl-2 dissociation and an anti-apoptotic effect (23,24). In the present study, the expression levels of PI3K/AKT signaling pathway-associated proteins were detected. It was demonstrated that inhibition of miR21-5p suppressed the PI3K/AKT/FOXO1 signaling pathway, suggesting that inhibiting the activation of the PI3K/AKT/FOXO1 signaling pathway may be a potential strategy for the treatment of TSCC.

In conclusion, downregulation of miR21-5p may effectively inhibit the proliferation and invasion of cancer cells and also promote the apoptosis of cancer cells. These data provide the basis for novel strategies for gene therapy of TSCC.

Acknowledgements

Not applicable.

Funding

The present study was funded by the Nature Science Foundation of Liaoning Province (grant no. 2015020326).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

ZW and LT conceived and designed the study. CL and ZT drafted the manuscript. Cell cultures were completed by ZT. The RT-qPCR protocol was performed by JT. Data analysis was performed by CL and ZX. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethical Committees of Jinzhou Medical University on October 26, 2016 (approval no. JZH2016052). Informed consent was obtained from all patients included in the present study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

TSCC

tongue squamous cell carcinoma

miRNA

microRNA

PDCD4

programmed cell death 4

WT

wild-type

References

1 

Weatherspoon DJ, Chattopadhyay A, Boroumand S and Garcia I: Oral cavity and oropharyngeal cancer incidence trends and disparities in the United States: 2000–2010. Cancer Epidemiol. 39:497–504. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Ramqvist T, Grün N and Dalianis T: Human papillomavirus and tonsillar and base of tongue cancer. Viruses. 7:1332–1343. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Karatas OF, Oner M, Abay A and Diyapoglu A: MicroRNAs in human tongue squamous cell carcinoma: From pathogenesis to therapeutic implications. Oral Oncol. 67:124–130. 2017. View Article : Google Scholar : PubMed/NCBI

4 

Sun L, Liang J, Wang Q, Li Z, Du Y and Xu X: MicroRNA-137 suppresses tongue squamous carcinoma cell proliferation, migration and invasion. Cell Prolif. 49:628–635. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Yuen PW, Lam KY, Chan AC, Wei WI and Lam LK: Clinicopathological analysis of local spread of carcinoma of the tongue. Am J Surg. 175:242–244. 1998. View Article : Google Scholar : PubMed/NCBI

6 

Rusthoven K, Ballonoff A, Raben D and Chen C: Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 112:345–351. 2008. View Article : Google Scholar : PubMed/NCBI

7 

Chu H, Jia B, Qiu X, Pan J, Sun X, Wang Z and Zhao J: Investigation of proliferation and migration of tongue squamous cell carcinoma promoted by three chemokines, MIP-3α, MIP-1β, and IP-10. Onco Targets Ther. 10:4193–4203. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Yan D, Cai X and Feng Y: miR-183 modulates cell apoptosis and proliferation in tongue squamous cell carcinoma SCC25 cell line. Oncol Res. 24:399–404. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Jiang Y, Zhang M, Guo T, Yang C, Zhang C and Hao J: MicroRNA-21-5p promotes proliferation of gastric cancer cells through targeting SMAD7. Onco Targets Ther. 11:4901–4911. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

11 

Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:e050052015. View Article : Google Scholar

12 

Betel D, Wilson M, Gabow A, Marks DS and Sander C: microRNA target predictions: The microRNA.org resource: Targets and expression. Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Sobin L, Gospodarowicz M and Wittekind C: UICC International Union Against Cancer TNM Classification of Malignant Tumors7th. West Sussex, Wiley-Blackwell; United Kingdom: 2009

14 

Fang H, Xie J, Zhang M, Zhao Z, Wan Y and Yao Y: miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res. 9:953–961. 2017.PubMed/NCBI

15 

Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, Xiao S and Lu H: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 88:1358–1366. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI

17 

Ricci C, Marzocchi C and Battistini S: MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells. 7(pii): E2192018. View Article : Google Scholar : PubMed/NCBI

18 

Bourguignon LY: Matrix hyaluronan promotes specific MicroRNA upregulation leading to drug resistance and tumor progression. Int J Mol Sci. 17:5172016. View Article : Google Scholar : PubMed/NCBI

19 

Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, et al: Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Target Oncol. 10:535–548. 2015. View Article : Google Scholar : PubMed/NCBI

20 

Liu ZL, Wang H, Liu J and Wang ZX: MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem. 372:35–45. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Wang Z, Yao W, Li K, Zheng N, Zheng C, Zhao X and Zheng S: Reduction of miR-21 induces SK-N-SH cell apoptosis and inhibits proliferation via PTEN/PDCD4. Oncol Lett. 13:4727–4733. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G and Naccarati A: MicroRNAs as markers of progression in cervical cancer: A systematic review. BMC Cancer. 18:6962018. View Article : Google Scholar : PubMed/NCBI

23 

Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V and Mukhtar H: Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231:52–60. 2008. View Article : Google Scholar : PubMed/NCBI

24 

Hao Y, Huang J, Ma Y, Chen W, Fan Q, Sun X, Shao M and Cai H: Asiatic acid inhibits proliferation, migration and induces apoptosis by regulating Pdcd4 via the PI3K/Akt/mTOR/p70S6K signaling pathway in human colon carcinoma cells. Oncol Lett. 15:8223–8230. 2018.PubMed/NCBI

Related Articles

Journal Cover

November-2019
Volume 18 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu C, Tong Z, Tan J, Xin Z, Wang Z and Tian L: MicroRNA‑21‑5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma. Exp Ther Med 18: 3543-3551, 2019.
APA
Liu, C., Tong, Z., Tan, J., Xin, Z., Wang, Z., & Tian, L. (2019). MicroRNA‑21‑5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma. Experimental and Therapeutic Medicine, 18, 3543-3551. https://doi.org/10.3892/etm.2019.7970
MLA
Liu, C., Tong, Z., Tan, J., Xin, Z., Wang, Z., Tian, L."MicroRNA‑21‑5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma". Experimental and Therapeutic Medicine 18.5 (2019): 3543-3551.
Chicago
Liu, C., Tong, Z., Tan, J., Xin, Z., Wang, Z., Tian, L."MicroRNA‑21‑5p targeting PDCD4 suppresses apoptosis via regulating the PI3K/AKT/FOXO1 signaling pathway in tongue squamous cell carcinoma". Experimental and Therapeutic Medicine 18, no. 5 (2019): 3543-3551. https://doi.org/10.3892/etm.2019.7970